Literature DB >> 17383573

Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Mei-Ping Kung1, Catherine Hou, Rajesh Goswami, Datta E Ponde, Michael R Kilbourn, Hank F Kung.   

Abstract

Labeling derivatives of dihydrotetrabenazine (DTBZ) with F-18 (T(1/2)=110 min) instead of C-11 (T(1/2)=20 min) would improve their utility and availability for imaging vesicular monoamine transporters (VMAT2) in clinical settings. The successful synthesis, reported previously, of two novel 9-fluoroalkyl(+/-)-DTBZ ligands prompted us to study the optically resolved active ligand 9-fluoropropyl-(+)-DTBZ (FP-(+)-DTBZ), which may have more promising characteristics. The inhibition constant (K(i)) estimated for FP-(+)-DTBZ (using [(3)H](+/-)-DTBZ as the labeled ligand in rat striatal homogenates) showed a lower value as compared to the racemic FP-(+/-)-DTBZ (0.10+/-0.01 vs 0.19+/-0.04 nM). The inactive isomer, FP-(-)-DTBZ, displayed a much lower binding affinity with a K(i) value >3000 nM. Biodistribution studies in mice after an iv injection of [(18)F]FP-(+)-DTBZ exhibited a ratio of striatum (ST, target) to cerebellum (CB, background) of 4.51 at 30 min postinjection, which is a higher value than previously obtained with the racemic ligand [(18)F]FP-(+/-)-DTBZ (ST/CB=2.95). Brain extraction at 30 min after the tracer injection in mice showed that >95% of the radioactivity corresponded to the parent, nonmetabolized, compound remaining in the ST, suggesting that the tracer has an excellent in vivo stability. Furthermore, localization of the tracer in the brain examined with ex vivo autoradiography displayed a typical distribution pattern consistent with VMAT2 sites. The highest labeling was observed in monoaminergic neuron regions (caudate putamen, olfactory tubercle, nucleus accumbens, substantia nigra, dorsal raphe and locus coerules). We also tested the selective labeling of this tracer at the dopamine neurons in unilateral-lesioned mice (treated with 6-hydroxydopamine). When [(18)F]FP-(+)-DTBZ and [(125)I]IPT ((N-(3'-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane, a selective marker for dopamine transporters (DATs) in dopaminergic neurons) were simultaneously injected into lesioned mice, we observed an excellent correlation (r=0.95) for these tracers. From these findings, we conclude that [(18)F]FP-(+)-DTBZ is a sensitive and selective tracer for VMAT2 binding sites and it may be useful for in vivo evaluation of diseases relating to changes of monoamine neuronal integrity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383573      PMCID: PMC1919419          DOI: 10.1016/j.nucmedbio.2006.12.005

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  30 in total

Review 1.  Dopamine receptors in Parkinson's disease: imaging studies.

Authors:  A Jon Stoessl; Raúl de la Fuente-Fernández
Journal:  Adv Neurol       Date:  2003

2.  [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain.

Authors:  D Scherman; R Raisman; A Ploska; Y Agid
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

3.  Increased ventral striatal monoaminergic innervation in Tourette syndrome.

Authors:  R L Albin; R A Koeppe; N I Bohnen; T E Nichols; P Meyer; K Wernette; S Minoshima; M R Kilbourn; K A Frey
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

4.  Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.

Authors:  M Kilbourn; K Frey
Journal:  Eur J Pharmacol       Date:  1996-06-27       Impact factor: 4.432

5.  Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters.

Authors:  M R Kilbourn; K A Frey; T Vander Borght; P S Sherman
Journal:  Nucl Med Biol       Date:  1996-05       Impact factor: 2.408

6.  [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity.

Authors:  T M Vander Borght; A A Sima; M R Kilbourn; T J Desmond; D E Kuhl; K A Frey
Journal:  Neuroscience       Date:  1995-10       Impact factor: 3.590

7.  Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific.

Authors:  M Kilbourn; L Lee; T Vander Borght; D Jewett; K Frey
Journal:  Eur J Pharmacol       Date:  1995-05-24       Impact factor: 4.432

8.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.

Authors:  R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum.

Authors:  Y Masuo; D Pélaprat; D Scherman; W Rostène
Journal:  Neurosci Lett       Date:  1990-06-22       Impact factor: 3.046

10.  IPT: a novel iodinated ligand for the CNS dopamine transporter.

Authors:  M P Kung; W D Essman; D Frederick; S Meegalla; M Goodman; M Mu; I Lucki; H F Kung
Journal:  Synapse       Date:  1995-08       Impact factor: 2.562

View more
  21 in total

1.  Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands.

Authors:  John Virostko; Joseph Henske; Laurent Vinet; Smaragda Lamprianou; Chunhua Dai; Aramandla Radhika; Ronald M Baldwin; Mohammad S Ansari; Franz Hefti; Daniel Skovronsky; Hank F Kung; Pedro L Herrera; Todd E Peterson; Paolo Meda; Alvin C Powers
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

Review 3.  PET/SPECT imaging agents for neurodegenerative diseases.

Authors:  Lin Zhu; Karl Ploessl; Hank F Kung
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

4.  Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes.

Authors:  Mika Naganawa; Keunpoong Lim; Nabeel B Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Kevan C Herold; Yiyun Huang; Paul Harris; Masanori Ichise; Gary W Cline; Richard E Carson
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

5.  Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [18F]FP-(+)-DTBZ.

Authors:  Yu Sun; Ning Zhao; Wangyuan Liu; Miao Liu; Zizhao Ju; Jun Li; Zhen Cheng; Xingdang Liu
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

6.  An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ.

Authors:  Chao Zhao; Chunyi Liu; Jie Tang; Yingjiao Xu; Minhao Xie; Zhengping Chen
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

7.  Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.

Authors:  Michael R Kilbourn; Brian Hockley; Lihsueh Lee; Catherine Hou; Rajesh Goswami; Datta E Ponde; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

8.  Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.

Authors:  Gary W Cline; Mika Naganawa; Laigao Chen; Kristin Chidsey; Santos Carvajal-Gonzalez; Sylvester Pawlak; Michelle Rossulek; Yanwei Zhang; Jason Bini; Timothy J McCarthy; Richard E Carson; Roberto A Calle
Journal:  Diabetologia       Date:  2018-05-02       Impact factor: 10.122

9.  Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboons.

Authors:  Mika Naganawa; Shu-Fei Lin; Keunpoong Lim; David Labaree; Jim Ropchan; Paul Harris; Yiyun Huang; Masanori Ichise; Richard E Carson; Gary W Cline
Journal:  Nucl Med Biol       Date:  2016-09-02       Impact factor: 2.408

10.  PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons.

Authors:  Paul E Harris; Michael D Farwell; Masanori Ichise
Journal:  Nucl Med Biol       Date:  2012-10-26       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.